Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine HCl ER in Prurigo Nodularis
NCT02174419Phase 3Completed
- Sponsor
- Trevi Therapeutics
- Start
- Mar 2015
- Primary completion
- Aug 2016
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of nalbuphine in prurigo nodularis (PN), sponsored by Trevi Therapeutics. Started Mar 2015; status: completed.
02
Drugs
nalbuphine
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT02174419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174419.